WP
ZBIO

Woodline Partners’s Zenas BioPharma ZBIO Stock Holding History

Woodline Partners’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15M Buy
590,539
+14
+0% +$278 0.05% 445
2026
Q1 		$11.5M Buy
+590,525
New +$13.3M 0.04% 474

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Woodline Partners's ZBIO Position: Q2 2026 in Review

Woodline Partners increased its Zenas BioPharma (ZBIO) stake by 0% in Q2 2026, buying an estimated $278 and bringing the position to 590,539 shares worth $15M. The position accounts for 0.05% of the portfolio, ranked #445.

Woodline Partners first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Woodline Partners held 590,539 shares of Zenas BioPharma worth $15M as of Q2 2026.
  • Woodline Partners bought 14 Zenas BioPharma shares in Q2 2026, an estimated $278.
  • Zenas BioPharma made up 0.05% of Woodline Partners's portfolio in Q2 2026, its #445 holding.
  • Woodline Partners first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.